Precigen (PGEN) Competitors $3.22 -0.04 (-1.08%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PGEN vs. KYMR, CRNX, PTGX, AKRO, MENS, SRRK, ZLAB, MIRM, ACAD, and AAPGShould you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), Protagonist Therapeutics (PTGX), Akero Therapeutics (AKRO), Jyong Biotech (MENS), Scholar Rock (SRRK), Zai Lab (ZLAB), Mirum Pharmaceuticals (MIRM), ACADIA Pharmaceuticals (ACAD), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Precigen vs. Its Competitors Kymera Therapeutics Crinetics Pharmaceuticals Protagonist Therapeutics Akero Therapeutics Jyong Biotech Scholar Rock Zai Lab Mirum Pharmaceuticals ACADIA Pharmaceuticals Ascentage Pharma Group International Kymera Therapeutics (NASDAQ:KYMR) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation. Is KYMR or PGEN more profitable? Kymera Therapeutics has a net margin of -616.03% compared to Precigen's net margin of -2,868.66%. Kymera Therapeutics' return on equity of -31.60% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-616.03% -31.60% -27.12% Precigen -2,868.66%-842.83%-78.98% Do analysts recommend KYMR or PGEN? Kymera Therapeutics currently has a consensus price target of $61.26, indicating a potential upside of 6.46%. Precigen has a consensus price target of $8.25, indicating a potential upside of 156.61%. Given Precigen's higher probable upside, analysts clearly believe Precigen is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 1 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.95Precigen 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable earnings & valuation, KYMR or PGEN? Precigen has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$47.07M87.41-$223.86M-$3.47-16.58Precigen$4.34M220.73-$126.24M-$0.42-7.65 Does the media refer more to KYMR or PGEN? In the previous week, Kymera Therapeutics and Kymera Therapeutics both had 11 articles in the media. Kymera Therapeutics' average media sentiment score of 0.48 beat Precigen's score of 0.39 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in KYMR or PGEN? 33.5% of Precigen shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 47.1% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, KYMR or PGEN? Kymera Therapeutics has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. SummaryKymera Therapeutics beats Precigen on 9 of the 16 factors compared between the two stocks. Get Precigen News Delivered to You Automatically Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PGEN vs. The Competition Export to ExcelMetricPrecigenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$957.98M$3.36B$6.12B$10.57BDividend YieldN/A2.28%5.66%4.70%P/E Ratio-7.6522.2286.0827.08Price / Sales220.73268.80534.29204.46Price / CashN/A46.3226.3031.09Price / Book24.739.9712.726.66Net Income-$126.24M-$52.35M$3.30B$275.86M7 Day Performance-11.43%6.36%4.34%3.06%1 Month Performance-26.26%12.02%7.82%10.52%1 Year Performance257.22%26.08%73.82%33.54% Precigen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PGENPrecigen4.569 of 5 stars$3.22-1.1%$8.25+156.6%+261.1%$957.98M$4.34M-7.65190Gap UpKYMRKymera Therapeutics1.9233 of 5 stars$58.50+4.0%$59.95+2.5%+34.5%$4.18B$47.07M-16.86170CRNXCrinetics Pharmaceuticals3.9318 of 5 stars$43.51-5.2%$73.20+68.2%-23.1%$4.10B$1.04M-10.59210Insider TradeHigh Trading VolumePTGXProtagonist Therapeutics2.0052 of 5 stars$65.14-3.4%$68.36+4.9%+46.1%$4.05B$434.43M93.06120Positive NewsHigh Trading VolumeAKROAkero Therapeutics3.7356 of 5 stars$47.62-0.3%$81.14+70.4%+63.2%$3.81BN/A-23.8130Positive NewsAnalyst UpgradeInsider TradeMENSJyong BiotechN/A$50.00-16.3%N/AN/A$3.80BN/A0.0031High Trading VolumeSRRKScholar Rock4.553 of 5 stars$38.36-1.0%$46.40+21.0%+405.0%$3.69B$33.19M-13.18140ZLABZai Lab3.0001 of 5 stars$32.93+4.1%$56.35+71.1%+28.0%$3.68B$398.99M-16.141,869Positive NewsMIRMMirum Pharmaceuticals3.4499 of 5 stars$72.85+0.1%$76.50+5.0%+85.8%$3.66B$336.89M-60.21140ACADACADIA Pharmaceuticals4.4691 of 5 stars$21.32+1.3%$29.12+36.6%+44.4%$3.60B$957.80M16.03510AAPGAscentage Pharma Group InternationalN/A$38.55+3.3%N/AN/A$3.59B$134.35M0.00600 Related Companies and Tools Related Companies KYMR Competitors CRNX Competitors PTGX Competitors AKRO Competitors MENS Competitors SRRK Competitors ZLAB Competitors MIRM Competitors ACAD Competitors AAPG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PGEN) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
